T. Rowe Price Associates, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 17,472,941 shares of 10X Genomics Inc. Class A common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 17,472,941 shares of 10X Genomics Class A common stock.
- Percent of class: The reported stake represents 14.5% of the outstanding class of securities, according to the filing.
- Sole voting power: T. Rowe Price disclosed sole voting power over 16,779,529 shares.
- Sole dispositive power: The firm reported sole dispositive power over all 17,472,941 shares, with no shared voting or dispositive power reported.
- Event date: The filing was triggered by an event dated September 30, 2026.
- Filer classification: T. Rowe Price Associates, Inc. is identified as an investment adviser (type "IA") organized in Maryland.
T. Rowe Price's Amended 13G Filing on 10X Genomics Class A Shares
T. Rowe Price Associates, Inc., an investment adviser incorporated in Maryland and headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 1 to its Schedule 13G regarding its holdings in 10X Genomics Inc. Class A common stock (NASDAQ:TXG), CUSIP 88025U109. The filing was dated November 16, 2026, with the triggering event date of September 30, 2026, according to the document.
According to the filing, T. Rowe Price reported aggregate beneficial ownership of 17,472,941 shares, equating to 14.5% of the class. Of that total, the firm disclosed sole voting power over 16,779,529 shares, while sole dispositive power extends to the full 17,472,941 shares. The filing reports zero shared voting power and zero shared dispositive power.
The filing includes a certification stating that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also states that T. Rowe Price "hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied." The document was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc.
What Was Disclosed
T. Rowe Price Associates, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 17,472,941 shares, or 14.5%, of 10X Genomics Inc. Class A common stock, with sole voting power over 16,779,529 shares, as of September 30, 2026.




Please wait processing your request...